Exenatide Once Weekly for the Treatment of Type 2 Diabetes Mellitus: Clinical Results in Subgroups of Patients Using Different Concomitant Medications

References

• . Drucker DJ. The biology of incretin hormones. Cell Metab. 2006; 3(3):153–165
   PubMed Web of Science ®Google Scholar
• . Holst JJ. The physiology of glucagon-like peptide 1. Physiol Rev. 2007;87(4):1409–1439
   PubMed Web of Science ®Google Scholar
• . Holst JJ, Gromada J. Role of incretin hormones in the regulation of insulin secretion in diabetic and nondiabetic humans. Am J Physiol Endocrinol Metab. 2004;287(2):E199–E206
   PubMed Web of Science ®Google Scholar
• . Orskov C, Holst JJ, Nielsen OV. Effect of truncated glucagon-like peptide-1 [proglucagon-(78-107) amide] on endocrine secretion from pig pancreas, antrum, and nonantral stomach. Endocrinology. 1988;123(4):2009–2013
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Heimesaat MM, Behle K, . Effects of glucagon-like peptide 1 on counterregulatory hormone responses, cognitive functions, and insulin secretion during hyperinsulinemic, stepped hypoglycemic clamp experiments in healthy volunteers. J Clin Endocrinol Metab. 2002;87(3):1239–1246
   PubMed Web of Science ®Google Scholar
• . Nauck MA, Niedereichholz U, Ettler R, . Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol. 1997;273(5 pt 1):E981–E988
   PubMed Web of Science ®Google Scholar
• . Tang—Christensen M, Larsen PJ, Göke R, . Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol. 1996;271(4 pt 2):R848–R856
   PubMedGoogle Scholar
• . Cersosimo E, Gastaldelli A, Cervera A, . Effect of exenatide on splanchnic and peripheral glucose metabolism in type 2 diabetic subjects. J Clin Endocrinol Metab. 2011;96(6):1763–1770
   PubMed Web of Science ®Google Scholar
• . Cervera A, Wajcberg E, Sriwijitkamol A, . Mechanism of action of exenatide to reduce postprandial hyperglycemia in type 2 diabetes. Am J Physiol Endocrinol Metab. 2008;294(5):E846–E852
   PubMed Web of Science ®Google Scholar
• . Kolterman OG, Buse JB, Fineman MS, . Synthetic exendin-4 (exenatide) significantly reduces postprandial and fasting plasma glucose in subjects with type 2 diabetes. J Clin Endocrinol Metab. 2003;88(7):3082–3089
   PubMed Web of Science ®Google Scholar
• . Tracy MA, Ward KL, Firouzabadian L, . Factors affecting the degradation rate of poly (lactide-co-glycolide) microspheres in vivo and in vitro. Biomaterials. 1999;20(11):1057–1062
   PubMed Web of Science ®Google Scholar
• . DeYoung MB, MacConell L, Sarin V, Trautmann M, Herbert P. Encapsulation of exenatide in poly-(D, L-lactide-co-glycolide) microspheres produced an investigational long-acting once-weekly formulation for type 2 diabetes. Diabetes Technol Ther. 2011;13(11):1145–1154
   PubMed Web of Science ®Google Scholar
• . Handelsman Y, Mechanick JI, Blonde L, ; AACE Task Force for Developing a Diabetes Comprehensive Care Plan. American Association of Clinical Endocrinologists Medical Guidelines for clinical practice for developing a diabetes mellitus comprehensive care plan: executive summary. Endocr Pract. 2011;17(2):287–302
   PubMed Web of Science ®Google Scholar
• . Inzucchi SE, Bergenstal RM, Buse JB, . Management of Hyperglycemia in Type 2 Diabetes: A Patient-Centered Approach: Position Statement of the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care. 2012;35(6):1364–1379
   PubMed Web of Science ®Google Scholar
• . Drucker D, Buse JB, Taylor K, ; DURATION-1 Study Group. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet. 2008;372(9645):1240–1250
   PubMed Web of Science ®Google Scholar
• . Bergenstal RM, Wysham C, MacConell L, ; DURATION-2 Study Group. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet. 2010;376(9739):431–439
   PubMed Web of Science ®Google Scholar
• . Diamant M, Van Gaal L, Stranks S, . Once weekly exenatide compared with insulin glargine titrated to target in patients with type 2 diabetes (DURATION-3): an open-label randomised trial. Lancet. 2010;375(9733):2234–2243
   PubMed Web of Science ®Google Scholar
• . Russell—Jones D, Cuddihy RM, Hanefeld M, ; DURATION-4 Study Group. Efficacy and safety of exenatide once weekly versus metformin, pioglitazone, and sitagliptin used as monotherapy in drug-naïve patients with type 2 diabetes (DURATION-4): a 26-week, double-blind study. Diabetes Care. 2012;35(2):252–258
   PubMed Web of Science ®Google Scholar
• . Blevins T, Pullman J, Malloy J, . DURATION-5: Exenatide once weekly resulted in greater improvements in glycemic control compared to exenatide twice daily in patients with type 2 diabetes. J Clin Endocrinol Metab. 2011;96(5):1301–1310
   PubMed Web of Science ®Google Scholar
• . Buse B, Nauck MA, Forst T, . Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study [abstract 75]. Diabetologia. 2011;54( suppl 1):S38
   Google Scholar
• . Ji LN, Onishi Y, Woo AC, . Efficacy and safety of exenatide once weekly versus exenatide twice daily in patients of Pan-Asian descent with type 2 diabetes. World Diabetes Congress Abstract Book. 2011; P1144
   Google Scholar
• . BYDUREON™ (exenatide extended-release for injectable suspension) [package insert]. San Diego, CA: Amylin Pharmaceuticals, Inc.; 2012
   Google Scholar
• . DeFronzo RA. Pharmacologic therapy for type 2 diabetes mellitus. Ann Intern Med. 1999;131(4):281–303
   PubMed Web of Science ®Google Scholar
• . Matthews DR, Charbonnel BH, Hanefeld M, Brunetti P, Schernthaner G. Long-term therapy with addition of pioglitazone to metformin compared with the addition of gliclazide to metformin in patients with type 2 diabetes: a randomized, comparative study. Diabetes Metab Res Rev. 2005;21(2):167–174
   PubMed Web of Science ®Google Scholar
• . Derosa G, Maffioli P. Effects of thiazolidinediones and sulfonylureas in patients with diabetes. Diabetes Technol Ther. 2010;12(6):491–501
   PubMed Web of Science ®Google Scholar
• . Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group. Lancet. 1998;352(9131):837–853
   PubMed Web of Science ®Google Scholar
• . Pencek R, Brunell SC, Li Y, Hoogwerf BJ, Malone J. Use of concomitant glucose-lowering therapies and associated treatment results observed in clinical trials of twice-daily exenatide. Endocr Pract. 2012;18(2):227–237
   PubMedGoogle Scholar